Denali Therapeutics Inc.
Compound, compositions, and methods
Last updated:
Abstract:
Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
Status:
Grant
Type:
Utility
Filling date:
18 Nov 2016
Issue date:
4 Jan 2022